Table 2. NSCLC patients’ biomarker values at the 2 times of interest.
| Marker | General population N = 59 |
Early progressors N = 29 |
Long responders N = 30 |
Univariate p |
Multivariate p |
|---|---|---|---|---|---|
| Just before the 1st infusion [baseline] | |||||
| Leu [Giga/L] | 8.1 [2.9–30.8] | 8.36 [3.1–17.67] | 7.97 [2.93–30.8] | 0.43 | |
| ANC [Giga/L] | 5.4 [0.7–28] | 5.9 [0.69–13.94] | 4.82 [1–28] | 0.22 | |
| ALC [Giga/L] | 1.6 [0.3–3.3] | 1.71 [0.45–2.56] | 1.56 [0.29–3.34] | 0.92 | |
| APC [Giga/L] | 298 [66–617] | 288 [66–617] | 309 [100–500] | 0.57 | |
| Albumin [g/L] | 36.4 [20.8–49.9] | 36 [23–49] | 36 [20–44] | 0.63 | |
| CRP [mg/L] | 23.5 [1–394] | 27.5 [1–394] | 20.5 [1–223] | 0.73 | |
| LDH [IU/L], | 391 [174–679] | 384 [285–597] | 428 [174–679] | 0.64 | |
| NLR, n [%] | |||||
| <5 | 21 [36.2] | 17 [59] | 20 [67] | 0.5 | |
| >5 | 37 [63] | 11 [38] | 10 [33] | ||
| PLR, n [%] | |||||
| <169 | 19 [32] | 9 [31] | 10 [33] | 0.3 | |
| 169–262 | 31 [53] | 17 [59] | 14 [47] | ||
| >262 | 8 [14] | 2 [3] | 6 [20] | ||
| LIPI, n of patients [%] | |||||
| No. of data collected | 16 [27] | 9 [31] | 7 [23] | 0.81 | |
| 0, good | 4 [25] | 3 [33] | 1 [14] | 0.53 | |
| 1, intermediate | 9 [56] | 5 [56] | 4 [57] | ||
| 2, poor | 3 [19] | 1 [11] | 2 [29] | ||
| ALI, n [%] | |||||
| <18 | 20 [34] | 9 [31] | 11 [37] | 0.86 | |
| >18 | 33 [56] | 17 [59] | 16 [53] | ||
| Just before the 4th infusion | |||||
| Leu [Giga/L], median [range] | 5 [2.7–25.1] | 9.77 [4.69–25.58] | 7.1 [2.7–25.1] | 0.0005 | |
| ANC [Giga/L], median [range] | 5 [1.7–23.7] | 7 [2.94–23.69] | 3.88 [1.7–7] | <0.0001 | |
| ALC [Giga/L], median [range] | 1.7 [0.4–3.7] | 1.69 [0.43–3] | 1.77 [0.37–3.59] | 0.29 | |
| APC [Giga/L], n, [%] median [range] | 284 [105–490] | 314 [123–490] | 261 [105–471] | 0.19 | |
| Albumin [g/L], median [range] | 36.7 [14–48.1] | 32.95 [14–48] | 37.65 [27–44] | 0.05 | |
| CRP [mg/L], median [range] | 22 [1–203] | 46 [1–203] | 13 [1–99] | 0.003 | |
| LDH [IU/L], median [range] | 354 [170–758] | 413 [196–758] | 325 [170–441] | 0.04 | |
| NLR n, [%] | |||||
| <5 | 39 [66] | 13 [45] | 26 [87] | 0.005 | |
| >5 | 19 [32] | 14 [48] | 5 [17] | ||
| PLR n, [%] | |||||
| <169 | 6 [44] | 10 [34] | 16 [53] | 0.37 | |
| 169–262 | 21 [36] | 10 [34] | 11 [37] | ||
| >262 | 11 [19] | 7 [24] | 4 [13] | ||
| LIPI n, [%] | |||||
| Data collected | 20 [33/34] | 11 [38] | 9 [30] | ||
| 0, good | 7 [35] | 1 [9] | 6 [67] | 0.01 | |
| 1, intermediate | 9 [45] | 6 [55] | 3 [33] | ||
| 2, poor | 4 [20] | 4 [36] | 0 | ||
| ALI n, [%] | |||||
| <18 | 18 [31] | 5 [17] | 13 [43] | 0.07 | |
| >18 | 34 [58] | 20 [69] | 14 [47] | ||
| Evolution | |||||
| ΔNLR, median [range] | –0.18 [–17.68–+14.99] | 0.65 [–13.24–+14.99] | –0.73 [–17.68–+2.91] | 0.01 | |
| ΔNLR < 1, n [%] | 43 [73] | 15 [52] | 28 [93] | 0.001 | 0.0007 |
| ΔNLR > 1, n [%] | 14 [24] | 12 [41] | 2 [7] | ||
| ΔANC [Giga/L], mean [±SD] | –0.3 ± 5 | 1.3 ± 4.8 | –1.7 ± 4.9 | 0.07 | |
| ΔALC [Giga/L] average[±SD] | 0.1 ± 0.7 | –0.024 ± 0.7 | 0.2 ± 0.6 | 0.02 | |
| ΔPLR, median [range] | 2.27 [–310–+395] | 16.44 [–222–+395] | –23.44 [–310–+145] | 0.008 |
Abbreviations: Leu, leukocytes; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; APC, absolute platelet count; CRP, C-reactive protein; LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocytes ratio; PLR, platelet-to-lymphocyte ratio; LIPI, Lung Immune Prognostic Index; ALI, Advanced Lung-cancer Inflammation Index; SD, standard deviation; n, number.